These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027 [TBL] [Abstract][Full Text] [Related]
8. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283 [No Abstract] [Full Text] [Related]
9. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. Boulton JG; Bourne JT Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233 [No Abstract] [Full Text] [Related]
10. Anti-TNF-alpha therapies: they are all the same (aren't they?). Mpofu S; Fatima F; Moots RJ Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736 [No Abstract] [Full Text] [Related]
11. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. Bassetti S; Wasmer S; Hasler P; Vogt T; Nogarth D; Frei R; Widmer AF J Rheumatol; 2005 Nov; 32(11):2125-9. PubMed ID: 16265689 [TBL] [Abstract][Full Text] [Related]
12. [Non tuberculous anti-TNF associated opportunistic infections]. Marie I; Guglielmino E Rev Med Interne; 2010 May; 31(5):353-60. PubMed ID: 20381217 [TBL] [Abstract][Full Text] [Related]
13. Nonserious infections: should there be cause for serious concerns? Dao KH; Herbert M; Habal N; Cush JJ Rheum Dis Clin North Am; 2012 Nov; 38(4):707-25. PubMed ID: 23137578 [TBL] [Abstract][Full Text] [Related]
14. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis. Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168 [No Abstract] [Full Text] [Related]
15. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199 [No Abstract] [Full Text] [Related]
16. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446 [TBL] [Abstract][Full Text] [Related]
17. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496 [TBL] [Abstract][Full Text] [Related]
18. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. Chen YM; Chen HH; Chen YH; Hsieh TY; Hsieh CW; Hung WT; Lan JL; Chen DY Ann Rheum Dis; 2015 Mar; 74(3):626-7. PubMed ID: 25452310 [No Abstract] [Full Text] [Related]
19. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491 [TBL] [Abstract][Full Text] [Related]